Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors
Mutsunori Murahashi(Jikei University School of Medicine), Kenzaburo Tani(Tokyo Medical University), Yoshihiko Maehara(Kyushu University), Junji Kishimoto(Kyushu University Hospital), Kazuo Tamura(Kindai University), Kazunari Yamada(Kyushu University Hospital), Tomotoshi Marumoto(Kyushu University), Hiroshi Fujii(Nara Women's University), Kazuhiro Mizumoto(National Cancer Center Hospital East), Yoshihiro Tanaka(National Defense Medical College), Hiroyuki Inoue(Fukuoka University), Eishi Baba(Kyushu University), Kazuyoshi Takeda(National Center of Neurology and Psychiatry), Masao Tanaka(Kyoto University), Yusuke Nakamura(Yokohama University of Pharmacy), Atsushi Takahashi(Juntendo University), Koichi Akashi(Kyushu University), Shinji Okano, Masaru Morita(Kyushu University), Koji Yoshida(Tokyo University of Science), Yasuki Hijikata(Kyushu University Hospital), Masakazu Hirakawa(Kyushu University Hospital), Takuya Tsunoda(Tokyo University of Science), Toshihiko Okazaki(Johns Hopkins University), Yoichi Nakanishi(RIKEN Center for Integrative Medical Sciences)
Cited by 62
Related Papers
Allelotype of Colorectal Carcinomas
|Science|1989|1.3k
MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors
|Cancer Cell|2004|701
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
|Nature Immunology|2017|639